

03 February 2026

Multiple Sclerosis Treatments

Q1. How many patients who have a current diagnosis of Multiple Sclerosis received treatment in the last six months with any of the following treatment regimens (July 2025 – December 2025)?

- | | |
|---|-----|
| • Ocrevus (ocrelizumab) IV (300mg/30ml) | 200 |
| • Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml) | 2 |
| • Kesimpta (ofatumumab) | 19 |
| • Briumvi (ublituximab) | 0 |
| • Mavenclad (cladribine) | 0 |
| • Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) | 102 |
| • Natalizumab (Tysabri and Tyruko) | 87 |

Q1a. Of the patients identified in question one, how many patients received the same treatment in the previous six-month period? (i.e. How many of the same patients received treatment with each treatment regimen in January 2025 to June 2025 AND July 2025 – December 2025?)

- | | |
|---|-----|
| • Ocrevus (ocrelizumab) IV (300mg/30ml) | 193 |
| • Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml) | 0 |
| • Kesimpta (ofatumumab) | 17 |
| • Briumvi (ublituximab) | 0 |
| • Mavenclad (cladribine) | 0 |
| • Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) | 100 |
| • Natalizumab (Tysabri and Tyruko) | 86 |

Q2. How many patients have received a new diagnosis for Multiple Sclerosis in the latest six-month period (July 2025 – December 2025)?

Q2a. Of the patients identified in question two, how many of these patients have received any of the following treatment regimens as their first treatment following their Multiple Sclerosis diagnosis?

- Ocrevus (ocrelizumab) IV (300mg/30ml)
- Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)
- Kesimpta (ofatumumab)
- Briumvi (ublituximab)
- Mavenclad (cladribine)
- Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)
- Natalizumab (Tysabri and Tyruko)

03 February 2026

Unfortunately, the service do not have the information for question 2. To date we have not recorded the date of MS diagnosis on the database, however the team will start recording the date of diagnosis from now so that we can answer this if further questions are asked. What we can confirm is that there is currently 2739 patients diagnosed with MS in the Belfast Trust.